Suppr超能文献

幽门螺杆菌治疗失败后的“挽救”方案。

"Rescue" regimens after Helicobacter pylori treatment failure.

作者信息

Gisbert Javier P

机构信息

Gastroenterology Unit, Hospital de la Princesa, Madrid, Spain.

出版信息

World J Gastroenterol. 2008 Sep 21;14(35):5385-402. doi: 10.3748/wjg.14.5385.

Abstract

Helicobacter pylori (H pylori) infection is the main cause of gastritis, gastroduodenal ulcer disease, and gastric cancer. After more than 20 years of experience in H pylori treatment, in my opinion, the ideal regimen to treat this infection is still to be found. Currently, apart from having to know first-line eradication regimens well, we must also be prepared to face treatment failures. Therefore, in designing a treatment strategy we should not focus on the results of primary therapy alone, but also on the final (overall) eradication rate. The choice of a "rescue" treatment depends on which treatment is used initially. If a clarithromycin-based regimen was used initially, a subsequent metronidazole-based treatment (quadruple therapy) may be used afterwards, and then a levofloxacin-based combination would be a third "rescue" option. Alternatively, it has recently been suggested that levofloxacin-based rescue therapy constitutes an encouraging second-line strategy, representing an alternative to quadruple therapy in patients with previous PPI-clarithromycin-amoxicillin failure, with the advantage of efficacy, simplicity and safety. In this case, a quadruple regimen may be reserved as a third-line rescue option. Finally, rifabutin-based rescue therapy constitutes an encouraging empirical fourth-line strategy after multiple previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin. Even after two consecutive failures, several studies have demonstrated that H pylori eradication can finally be achieved in almost all patients if several rescue therapies are consecutively given. Therefore, the attitude in H pylori eradication therapy failure, even after two or more unsuccessful attempts, should be to fight and not to surrender.

摘要

幽门螺杆菌(H pylori)感染是胃炎、胃十二指肠溃疡病和胃癌的主要病因。在幽门螺杆菌治疗领域积累了20多年的经验后,在我看来,治疗这种感染的理想方案仍有待探索。目前,除了必须熟知一线根除方案外,我们还必须做好应对治疗失败的准备。因此,在设计治疗策略时,我们不应仅关注初始治疗的结果,还应关注最终(总体)根除率。“补救”治疗的选择取决于最初使用的治疗方案。如果最初使用的是以克拉霉素为基础的方案,随后可使用以甲硝唑为基础的治疗(四联疗法),然后以左氧氟沙星为基础的联合用药将是第三种“补救”选择。或者,最近有人提出,以左氧氟沙星为基础的补救治疗是一种令人鼓舞的二线策略,对于先前使用质子泵抑制剂-克拉霉素-阿莫西林治疗失败的患者,它可作为四联疗法的替代方案,具有疗效好、用药简单和安全性高的优点。在这种情况下,四联方案可留作三线补救选择。最后,在先前多次使用阿莫西林、克拉霉素、甲硝唑、四环素和左氧氟沙星等关键抗生素根除失败后,以利福布汀为基础的补救治疗是一种令人鼓舞的经验性四线策略。即使连续两次治疗失败,多项研究表明,如果连续给予几种补救治疗,几乎所有患者最终都能实现幽门螺杆菌的根除。因此,即使经过两次或更多次不成功的尝试,对于幽门螺杆菌根除治疗失败的态度也应该是抗争而不是放弃。

相似文献

1
"Rescue" regimens after Helicobacter pylori treatment failure.
World J Gastroenterol. 2008 Sep 21;14(35):5385-402. doi: 10.3748/wjg.14.5385.
2
Second-line rescue therapy of helicobacter pylori infection.
Therap Adv Gastroenterol. 2009 Nov;2(6):331-56. doi: 10.1177/1756283X09347109.
3
Rescue Therapy for Helicobacter pylori Infection 2012.
Gastroenterol Res Pract. 2012;2012:974594. doi: 10.1155/2012/974594. Epub 2012 Feb 28.
4
'Rescue' therapies for the management of Helicobacter pylori infection.
Dig Dis. 2006;24(1-2):113-30. doi: 10.1159/000090315.
5
Helicobacter pylori "rescue" therapy after failure of two eradication treatments.
Helicobacter. 2005 Oct;10(5):363-72. doi: 10.1111/j.1523-5378.2005.00324.x.
6
Helicobacter pylori eradication therapy.
Future Microbiol. 2010 Apr;5(4):639-48. doi: 10.2217/fmb.10.25.
8
[Rescue therapy after Helicobacter pylori eradication failure].
Gastroenterol Hepatol. 2011 Feb;34(2):89-99. doi: 10.1016/j.gastrohep.2010.10.013.
9
Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures.
Aliment Pharmacol Ther. 2012 Apr;35(8):941-7. doi: 10.1111/j.1365-2036.2012.05053.x. Epub 2012 Feb 28.
10
Second-line rescue treatment of infection: Where are we now?
World J Gastroenterol. 2018 Oct 28;24(40):4548-4553. doi: 10.3748/wjg.v24.i40.4548.

引用本文的文献

2
Vonoprazan-amoxicillin dual regimen with as a rescue therapy for : Current perspectives and implications.
World J Gastroenterol. 2024 Mar 14;30(10):1280-1286. doi: 10.3748/wjg.v30.i10.1280.
3
Research on antibiotic resistance in : a bibliometric analysis of the past decade.
Front Microbiol. 2023 Jun 14;14:1208157. doi: 10.3389/fmicb.2023.1208157. eCollection 2023.
4
Recombinant Vaccine Delivery Vehicle: A Promising Tool to Treat Infections and Combat Antimicrobial Resistance.
Antibiotics (Basel). 2022 Nov 25;11(12):1701. doi: 10.3390/antibiotics11121701.
5
rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy.
JGH Open. 2021 Jan 23;5(2):307-311. doi: 10.1002/jgh3.12492. eCollection 2021 Feb.
6
Rifabutin for the Treatment of Infection: A Review.
Pathogens. 2020 Dec 28;10(1):15. doi: 10.3390/pathogens10010015.
7
Optimization Strategies Aimed to Increase the Efficacy of Eradication Therapies with Quinolones.
Molecules. 2020 Nov 2;25(21):5084. doi: 10.3390/molecules25215084.
8
Oncogenicity: Mechanism, Prevention, and Risk Factors.
ScientificWorldJournal. 2020 Jul 12;2020:3018326. doi: 10.1155/2020/3018326. eCollection 2020.
10
Temporin-SHa and Its Analogs as Potential Candidates for the Treatment of .
Biomolecules. 2019 Oct 11;9(10):598. doi: 10.3390/biom9100598.

本文引用的文献

2
Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients.
Aliment Pharmacol Ther. 2008 Feb 15;27(4):346-54. doi: 10.1111/j.1365-2036.2007.03573.x. Epub 2007 Nov 12.
3
Evolution of Helicobacter pylori therapy from a meta-analytical perspective.
Helicobacter. 2007 Nov;12 Suppl 2:50-8. doi: 10.1111/j.1523-5378.2007.00576.x.
4
An alternative salvage regimen for Helicobacter pylori-resistant patients with heart failure.
Cardiology. 2008;110(2):112-5. doi: 10.1159/000110489. Epub 2007 Oct 31.
5
The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice.
Aliment Pharmacol Ther. 2007 Dec;26(11-12):1537-42. doi: 10.1111/j.1365-2036.2007.03531.x. Epub 2007 Sep 28.
6
Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance.
Dig Liver Dis. 2007 Nov;39(11):1001-5. doi: 10.1016/j.dld.2007.06.016. Epub 2007 Sep 21.
7
Nitrofuran-based regimens for the eradication of Helicobacter pylori infection.
J Gastroenterol Hepatol. 2007 Oct;22(10):1571-81. doi: 10.1111/j.1440-1746.2007.05082.x.
9
Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.
Am J Gastroenterol. 2008 Jan;103(1):71-6. doi: 10.1111/j.1572-0241.2007.01500.x. Epub 2007 Aug 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验